Previous 10 | Next 10 |
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Intercept Pharmaceuticals Inc (ICPT) Q1 2021 Earnings Call Tra...
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2021 Earnings Conference Call May 6, 2021, 8:30 am ET Company Participants Lisa DeFrancesco - SVP, Corporate Affairs & IR Jerry Durso - President & CEO Rocco Venezia - CAO, Acting CFO & Treasurer Gail Cawkwell - Interim CMO Linda Richardso...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Intercept Pharma (ICPT): Q1 GAAP EPS of -$1.22 beats by $0.27.Revenue of $81.7M (+12.5% Y/Y) beats by $0.46M.Narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million to $340 million and reiterates Non-GAAP a...
Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million to $340 million and reiterates Non-G...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is -$1.42 (+50.3% Y/Y) and the consensus Revenue Estimate is $81.23M (+11.8% Y/Y).Over the last 2 years, ICPT has beaten EPS estimates 50% of the tim...
The Phase 2 data has been excellent while the company is most likely to present strong data for its Phase 3 MAESTRO-NAFLD-1 trial in late 2021. Despite the volatility in late 2018, Madrigal is determined to make a huge comeback. The vast market for NASH and NAFLD-1 makes the innov...
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2021 financial result...
Founded in 2002, Intercept Pharmaceuticals (NASDAQ: ICPT) is a biotech company whose only drug treats liver diseases. Intercept's drug, obeticholic acid, was approved by the U.S. Food and Drug Administration (FDA) in 2016 for treating primary biliary cholangitis, a chronic dise...
David Einhorn's 13F stock portfolio value increased from $1.22B to $1.66B this quarter. Greenlight increased Atlas Air Worldwide, Teck Resources, and Resideo Technologies while reducing AerCap Holdings, Chemours, and NCR Corp. during the quarter. The largest three positions are at...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...